Potential of antiviral peptide-based SARS-CoV-2 inactivators to combat COVID-19.
Ontology highlight
ABSTRACT: The appearance of new variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the lack of effective antiviral therapeutics for coronavirus disease 2019 (COVID-19), a highly infectious disease caused by the virus, demands the search for alternative therapies. Most antiviral drugs known are passive defenders which must enter the cell to execute their function and suffer from concerns such as permeability and effectiveness, therefore in this current study, we aim to identify peptide inactivators that can act without entering the cells. SARS-CoV-2 spike protein is an essential protein that plays a major role in binding to the host receptor angiotensin-converting enzyme 2 and mediates the viral cell membrane fusion process. SARS vaccines and treatments have also been develo
SUBMITTER: Gurung AB
PROVIDER: S-EPMC9165783 | biostudies-literature | 2022
REPOSITORIES: biostudies-literature
ACCESS DATA